QSAR Lab’s Post

A friend asked me “Simon, what’s up with your large-scale multi-omics 🧬 presentation tomorrow at NextGen Omics conference??” We’re struggling with a proper single-omic workflow!! Well, the future of precision medicine 💊 is there and patients can’t wait. We all have family members and friends who want to live a better life. ❤️ ⏰ When: Tomorrow 9:40 AM. Make sure to swing by booth #17 and meet the Code Ocean team to have a chat, grab some of our latest swag, or see a demo! #bioinformatics #nextgenomics #biotech

Check it out and visualize high throughput flow cytometry in action. #automation #cytometry #target #marker #immunotherapy #immuno #vaccin #CAR #phenotyping #screening #tumor #leukemia #lymphoma #immunooncology #autoummunity #drugdevelopment

From Discovery to Delivery: A Rapid and Targeted Proteomics Workflow for Monitoring Chinese Hamster Ovary Biomanufacturing Traditional methods for developing Chinese hamster ovary (CHO) cell lines and processes are time-consuming and often lack precision. Charles Eldrid has developed a rapid and targeted proteomics workflow to identify key biomarkers that drive optimal bioreactor performance. Harnessing the power of advanced proteomics, has the potential to accelerate the discovery and development of high-performing cell lines, leading to faster and more efficient biopharmaceutical production.

Subscribe to receive exclusive updates from #StageBioNews.

Very excited about SLAS next week! If you didn’t know already: it’s finally possible to do morphological profiling on live cells! Interested in capturing new insights on cell biology with real time data? Come see us at Posters 1056-A and 1158-C SLAS (Society for Laboratory Automation and Screening) #livecellimaging #livecellpainting #morphologicalprofiling #highcontentscreening

At the recent 2nd Precision Medicine in IBD Summit, it was our honor to collaborate with DNAnexus in a session that explored the transformative power of leveraging high-value multiomics data alongside an advanced analysis platform to accelerate IBD drug discovery research. Couldn't attend the session? We've got you covered! Our latest blog captures the essential takeaways from the presentation, including the impactful work Ovation and DNAnexus are doing to help researchers use multiomics data to gain faster insights into IBD. Check out the event recap on our blog: https://lnkd.in/eZBNFJYt #precisionmedicine #IBDresearch #multiomics

How can virtual humans impact #cardiacsafety? “With our tool we can study in different kinds of patients what is going to be the result of taking that pill, unleashing some problems in the heart…” Watch the full interview with our CTO Mariano Vazquez conducted by IBTV during #BIOSanDiego, to learn more about our product and collaborations. 🔗 https://lnkd.in/d3bmMfB3 Contact us at contact@elem.bio if you want to understand better our contribution to cardiac safety! #biotechnology #cardiology #drugsafety

We're peresent at the ACS Conference! Representing us at the event is Kishore V Renduchintala, Our Executive Vice President & Head of Discovery Services and Vidya Sagar K. - Head of Business Development - Discovery Services. Meet us at the ACS Conference to learn more about Laxai and explore a partnership that could revolutionise the approach to drug discovery and development. To book a meeting, reach out to bd@laxai.com. We look forward to connecting with you at the event! hashtag #ACSConference #LAXAI #DrugDiscovery #CRDMO #SmallMolecules

BREAKING NEWS ❗️ We're excited to share an update on our latest project that’s set to bring significant advancements to antibody discovery. 🚀 Introducing Vorizon: Our Next-Generation VHH Library We’ve completed the development of #Vorizon, a new VHH library that’s the result of months of focused research and innovation. 🔍 What Makes Vorizon Unique? · Advanced VHH Patterns: Our collaboration with the University of Aston and the University of Nottingham about #MachineLearning has uncovered new VHH sequence patterns, enhancing library precision. · Pre-Humanised Frameworks: Vorizon integrates pre-humanised CDR sequences, retaining VHHs’ small size and stability, ready for therapeutic use. · Rigorous Testing: Vorizon is now in the final quality checks against immuno-oncology targets, ensuring it performs as well or better than our existing libraries. 🌅 Looking Ahead As we approach Vorizon’s full launch next year, we’ll keep you updated on its progress and share insights along the way. This is just the start, and we’re eager to see how Vorizon will contribute to the future of #AntibodyDiscovery.